PNPLA3 and steatosis: From a therapeutical point of view, efforts directed to lower the expression of PNPLA3 have been demonstrated to mitigate hepatic steatosis, liver inflammation, and fibrosis stage [143] in mice, while in humans, a gene variant associated with decreased expression of PNPLA3 reduced the effects of I148M on susceptibility to liver damage and steatosis [144].